Clinical trials: Hydroxychloroquine
- Condition Hydroxychloroquine
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
Sarcoma, Clear Cell
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
The goal of this trial in Phase I is to determine the maximally tolerated dose (MTD) of hydroxychloroquine in combination with devimistat in patients with relapsed or refractory Clear Cell Sarcomas of the Soft Tissue and to…
- Trial name
- NCT04593758
- Testing
- CPI-613 + Hydroxychloroquine
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cornerstone Pharmaceuticals